Use of Linezolid, an Oxazolidinone, in the Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections

December 2, 2017 at 8:00 am

Clinical Infectious Diseases January 2000 V.30 N.1 P.146-151

Jason W. Chien, Michelle L. Kucia, and Robert A. Salata

Division of Infectious Diseases, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Cleveland, Ohio

We report our experience with linezolid in an investigation of its use against resistant gram-positive bacterial infections.

Fifteen patients who had renal failure (n = 6), recent liver transplantation (n = 5) or surgery (n = 6), cancer (n = 3), endocarditis (n = 2), or human im-munodeficiency virus infection (n = 1), along with infections due to vancomycin-resistant entero-coccus (VRE), and 2 patients with infections due to methicillin-resistant Staphylococcus species who had adverse reactions to vancomycin were treated with linezolid (600 mg every 12 h for 5–42 days (mean ± SD, 20.5 ± 3.5 days).

Abscess drainage or prosthetic device removal was undertaken. Microbiological cure occurred in all 10 patients who completed therapy, and all 7 patients alive at follow-up were free of infection.

No deaths were attributable to the index infection. Adverse events associated with linezolid use were mild leukopenia in 1 patient and nausea in another.

It appears that administration of linezolid, in conjunction with surgical intervention or device removal, is an effective treatment option for serious resistant gram-positive bacterial infections.



Entry filed under: Antimicrobianos, Bacterias, Bacteriemias, Metodos diagnosticos, REPORTS, Resistencia bacteriana, Sepsis, Update.

Outbreak of a Multiresistant Klebsiella pneumoniae Strain in an Intensive Care Unit: Antibiotic Use as Risk Factor for Colonization and Infection Predictors of pneumonia in lower respiratory tract infections: 3C prospective cough complication cohort study


December 2017
« Nov   Jan »

Most Recent Posts

%d bloggers like this: